AVP and metabolic dysfunction-associated steatotic liver disease: Obese patients with biopsy-proven NAFLD (obese+/NAFLD+, 53%) had significantly higher copeptin levels than obese individuals without NAFLD (obese+/NAFLD−) (obese+/NAFLD+ 9.5 ± 4.9 pmol/L vs obese+/NAFLD− 6.4 ± 2.6 pmol/L, p = 0.004).